• Home
  • The University of Arizona Global Campus
  • Personal & Organizational Ethics PHI 445
  • Ethics in the Pharmaceutical Industry

Ethics in the Pharmaceutical Industry

I will introduce the case study I have chosen, Merk Pharmaceuticals. According to the history of Merck & Co, they are on the list of being one of the largest pharmaceutical company in the world ("A history of... Merck & Co - pharmaphorum.com." 30 May. 2013). Merck & Co, main headquarters located in New Jersey, with an average of 82,000 staff worldwide or more since the year 2013 ("A history of... Merck & Co - pharmaphorum.com." 30 May. 2013). For more than 125 years, the company has been bringing forward medicine and vaccines for the United States and Canada. Their mission is to save and improve lives for the world's most challenging diseases. Merck's commitment demonstrates Deontology. They focus on the well-being of patients and the entire populations. The World Health Organization provides access to health care by providing comprehensive policies, programs, and partnerships. Despite any criticism or wrongdoing, Merck continues to be the largest pharmaceutical company in the world leading forefront of research to treat and prevent these diseases that threaten the lives of people and animals. These diseases are cancer, HIV, Ebola, and many other infectious diseases, they also treat and prevent diseases for animals. According to a source reported by the NBC News in 2021, Merck discontinued developing its two Covid-19 vaccine candidates. The after early clinical trial results showed an "inferior" immune response, according to NBC News (2021). Merck was slow to develop a vaccine against the virus, which has killed more than 2 million people worldwide and infected nearly 100 million (2021). In a statement on its website, Merck said that it was discontinuing the development of two vaccine candidates (2021). The results of the studies showed that both vaccines it worked on did not work. One produced a lower immune response than the disease; even the second had a weak immune response. The results showed Merck's Phase 1 clinical studies on vaccines. Both were tested and generally well tolerated in these studies, but results showed that the immune responses were inferior to those observed after natural infections and those reported for other cases like the COVID19 and SARS vaccines. The clinical testing showed that the two vaccine candidates that Merck was testing were "not effective." Probably lower than fifty percent efficiency. At least a dozen other attempts by other companies throughout the world also failed most of them due to a lack of efficacy and safety concerns that were halted abruptly. The right to try (RTT) laws are potentially beneficial to people facing severe or terminal illnesses. Standard treatments are not effective or for which no medicines have yet been approved. The FDA's treatment approval process can be lengthy and complicated, often involving year-long clinical, animal, and human trials before being available to the public if Merck has an experimental treatment for a terminal condition. They have not yet determined whether it is safe to use; an RTT law would permit someone with that condition to be a human guinea pig forgoing the usual